Global Pediatric Drugs & Vaccines Industry Analysis 2016-2018: Strategic Business Forecasts to 2024 - New Product Approvals and Pipeline: A Key Growth Propeller

DUBLIN, July 5, 2018 /PRNewswire/ --

The "Pediatric Drugs and Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ Million by the following Therapeutic Class:

• Pediatric Vaccines
• Pediatric Hormones
• Allergy & Respiratory Drugs
• Anti-infective Drugs
• CNS Drugs
• Other Pediatric Drugs

The Pediatric Vaccines market is also analyzed by the following Type:

• Combinations
• Hepatitis
• MMR
• Varicella
• Poliovirus
• Pneumococcal
• Others

The report profiles 90 companies including many key and niche players such as:

• Abbott Laboratories (USA)
• Allergan, Inc. (USA)
• Amgen, Inc. (USA)
• AstraZeneca Plc. (UK)
• Boehringer Ingelheim GmbH (Germany)
• Bristol-Myers Squibb Company (USA)
• Eli Lilly and Company (USA)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Genentech, Inc. (USA)
• GlaxoSmithKline plc. (UK)
• Janssen Biologics B.V. (USA)
• Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
• Merck & Co., Inc. (USA)
• Novartis AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Pfizer, Inc. (USA)
• Sanofi S.A (France)
• Shionogi Inc. (USA)
• Shire Pharmaceuticals Group Plc. (UK) 

Key Topics Covered

1. INDUSTRY OVERVIEW
Pediatrics: A Highly Underserved and Undervalued Group
Pediatric Drugs Market
An Abode of Opportunities
The United States: Largest Market for Pediatric Drugs and Vaccines
Developing Markets to Witness Faster Growth
Antibiotics: Largest Selling Drug Classes
Pediatric Vaccines Market
On High Growth Trajectory
Supply and Demand Dynamics of the Global Vaccine Market
UNICEF Addresses BCG Vaccine Supply Shortage
Access to Vaccines Index: Aiding Increased Access to Vaccines
Recent Advancements/Achievements in the Pediatric Vaccines Space

2. GROWTH DRIVERS AND MARKET TRENDS
Pediatric Exclusivity Drives Manufacturers' Interest
Pediatric Exclusitivity Granted to Branded Drugs
New Product Approvals and Pipeline
A Key Growth Propeller
Recent Pediatric Drug Approvals: 2015-2017
Pediatric Drug Approvals: 2011-2014
Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017)
Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017)
Potential for Pediatric Drugs Against Obesity-related Conditions
List of Pediatric Drugs for Congestive Heart Failure Treatment
Recent Findings to Help Save Children's Lives
Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials
Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials
Modeling & Simulation
A Powerful Tool for Pediatric Clinical Study Sponsors
Pharmacometrics Approaches Gain Traction Among US and EU Researchers
Challenges Associated with Adoption of Pharmacometric Approach
Guidelines for Conducting Ethically Correct Clinical Trials
Pediatric Drug Market
Is Off-label Prescription Justified?
Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine
High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination
Vaccine Refusal by Parents
A Growing Trend in the US Market
Orphan Drugs for Pediatric Use Gain Popularity
List of FDA Approved Orphan Drugs: 2015-2016
List of FDA Designated Orphan Drugs: 2015-2017
Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs
Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections
Approved Pediatric Antiretroviral Drugs for HIV Treatment
Highly Fragmented Growth Hormone Market

3. PEDIATRIC VACCINES MARKET
Immunization Coverage
Market Share of Leading Pediatric Vaccine Manufacturers
Phase III Completed Pediatric Vaccines: 2015-2017 (As of July 2017)
Ongoing Phase III Pediatric Vaccines Clinical Trials: 2015- 2017 (As of July 2017)
Pediatric Vaccine Types
Hemophilus Influenza Type B Vaccine
Available Hib and Combination Vaccines
Diphtheria/Tetanus/Pertussis Vaccines (DTaP Vaccines)
Available DTaP and Combination Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccine
Measles/Mumps/Rubella (MMR) Vaccines
Rotavirus Vaccines
Polio Vaccines
Varicella Virus Vaccine (VAR)
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Combination Vaccines
Rising Women Workforce Propels Pediatric Vaccines Growth

4. PEDIATRIC DISEASES
OVERVIEW, STATISTICS & TREATMENT
Influenza
Treatment
Urinary Tract Infection (UTI)
Prevalence
Treatment
Mumps
Complications Related to Mumps
Prevention of Mumps in children
Incidence
Candidiasis
Fifth Disease
Molluscum Contagiosum
Roseola
Tetanus
Whooping Cough
Allergy and Respiratory Diseases
Prevalence Statistics
Diphtheria
Incidence and Mortality Statistics
Upper Respiratory Infection (Common Cold)
Diagnosis & Treatment
Measles
Statistics
Asthma
Prevalence
Central Nervous System Disorders
Mental Disorders
Attention Deficit Hyperactivity Disorder
Prevalence
Depression
Prevalence
Epilepsy
Epilepsy Treatment
Incidence and Prevalence of Epilepsy in the US
Hormonal Disorders
Diabetes Mellitus
Hypothyroidism
Hypothyroidism in Infants and Children
Symptoms and Diagnosis
Treatment of Hypothyroidism in Children
Precocious Puberty
Symptoms and Signs
Signs of Early Puberty in Girls and Boys
Treatment
Hypopituitarism
Treatment
Lymphocytic Thyroiditis
Symptoms
Treatment
Other Diseases
Cardiovascular Diseases
Cancers

5. LIST OF SELECT FDA APPROVED PEDIATRIC DRUGS

6. PRODUCT INTRODUCTIONS/APPROVALS
Actelion Obtains "Epoprostenol Act" Label Extension for Pediatric PAH Patients in Japan
FDA Approves Merck's KEYTRUDA (pembrolizumab)
Novartis Announces FDAs Acceptance of Company's CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with r/r B-cell ALL
Boehringer Ingelheim's Tiotropium Respimat Receives FDA Approval Expansion for Maintenance Treatment of Asthma in Children
Sanofi Pasteur terminates a Vaccine Joint-venture with MSD
ViiV Healthcare Announces the Changed Opinion of CHMP to Lower the Age and Weight Limit for Tivicay (dolutegravir) in Children and Adolescents Living with HIV in Europe
Shire Announces FDA Approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical settings
Pfizer Inc. Announces PHASE 3 TRIALs Positive Results of LYRICA (PREGABALIN) Capsules CV and Oral Solution CV for Treating Pediatric Epilepsy Patients
Pfizer's Prevenar 13 Receives Approval for Use in Infants and Children in China
Simponi Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Sanofi Pasteur Launches India's first innovative 6-in-1 vaccine
Shire launches pediatric indication for immunodeficiency treatment HyQvia in Europe
Novo Nordisk's NovoRapid receives positive opinion from CHMP for extended use in European Union for children as young as one year old
Boehringer Ingelheim Announces the Ability of Tiotropium Respimat for improving lung function in children aged 6-11
FDA Approves BLINCYTO (blinatumomab) for Use in Pediatric Patients with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
FDA Approves Genentech's Xolair (omalizumab) for Allergic Asthma in Children
Novartis Receives EU Approval for Revolade as First-in-class Therapy for Children Aged 1 year and above with Chronic ITP
Pandemic Influenza Vaccine Receives Positive Opinion from CHMP
GSK's Advair Diskus Exhibits Primary Endpoint in paediatric LABA' Safety Study
FDA Accepts Amgen's Supplemental Biologics License Application (sBLA) for The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients with Chronic Severe Plaque Psoriasis
Genentech's supplemental Biologics License Application (sBLA) Receives Acceptance from FDA for reviewing Xolair ( omalizumab)
Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children
Shire Reports Topline Results from Phase 2 Studies in Children with Alagille Syndrome
FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients for Immediate Release
Sanofi K.K. and Aptalis Pharmaceutical Technologies Launches Allegra Dry Syrup 5% in Japan
Sanofi Pasteur Announces Availability of First Doses of Injectable Polio Vaccine ShanIPV(TM) in Near Future for Indian Infants
Shire receives CHMP's Positive Opinion in Europe for INTUNIV
Novo Nordisk's Levemir Receives Positive Opinion from CHMP for Extended use in Children as Young as one Year Old

7. RECENT INDUSTRY ACTIVITY
Johnson & Johnson Acquires Actelion
Sanofi Collaborates with MedImmune for development and Commercialization of Monoclonal Antibody for Preventing RSV
GSK Intends to Opens a New Global Vaccines R&D Center in Rockville, MD, USA
Lupin and Monosol Rx Enters into Licensing Agreement for Developing Multiple Pediatric-Focused Products
ICGEB & Sun Pharma Enters into New Exclusive Collaboration to Develop Novel Dengue Vaccine for India & Global Markets
Actelion Initiates Phase III Study of Macitentan (Opsumit) for treating Children with PAH
Shire and Cincinnati Children's Establishes Rare Disease Research Collaboration

8. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (USA)
Allergan, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
Merck & Co., Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Shire Pharmaceuticals Group Plc. (UK)

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 90 (including Divisions/Subsidiaries 103)

• The United States (53)
• Canada (3)
• Japan (7)
• Europe (33)
• France (3)
• Germany (1)
• The United Kingdom (6)
• Italy (1)
• Rest of Europe (22)
• Asia-Pacific (Excluding Japan) (7)

For more information about this report visit https://www.researchandmarkets.com/research/zbsx9x/global_pediatric?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com